双侧同日玻璃体腔抗VEGF注射后眼内炎发生率
结论认为双侧同日注射后单侧眼内炎发生率低,与既往单侧注射研究相当,支持该治疗的安全性。
要点
- 无双侧眼内炎病例,无患者发生超过1次眼内炎。
- 单侧眼内炎发生率低,与既往单侧注射研究相当。
核心结论
- 在大规模双侧同日玻璃体腔抗VEGF注射队列中,无双侧眼内炎病例,单侧眼内炎总体发生率低且与既往单侧注射研究相当,结果支持该治疗的安全性。
研究设计与样本
- 回顾性队列研究,电子查询一家大型学术私立诊所2012年4月1日至2017年8月21日间所有行双侧玻璃体腔抗VEGF注射的就诊记录,纳入诊断为新血管性年龄相关性黄斑变性、糖尿病性黄斑水肿或视网膜静脉阻塞的患者。
主要发现
- 无双侧眼内炎病例,无患者发生超过1次眼内炎。
- 注射最常见的两个适应证为新血管性年龄相关性黄斑变性(占患者54.3%)和糖尿病性黄斑水肿(占患者35.4%)。
关键数值与推荐
- 双侧眼内炎病例数:0例。
- 同一患者眼内炎发生超过1次:0例。
临床怎么用
- 该大样本队列中双侧同日玻璃体腔抗VEGF注射后无双侧眼内炎病例,单侧眼内炎发生率低且与既往单侧注射研究相当,结果支持该治疗的安全性。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate practice patterns for bilateral same-day intravitreal anti-vascular endothelial growth factor (VEGF) injections and determine the rate of unilateral and bilateral postinjection endophthalmitis after bilateral same-day intravitreal anti-VEGF injections. DESIGN: Retrospective cohort study. METHODS: The records of a large academic private practice were electronically queried for all office visits, during which bilateral intravitreal anti-VEGF injections were performed between April 1, 2012 and August 21, 2017 for patients with a diagnosis of neovascular age-related macular degeneration, diabetic macular edema, or retinal vein occlusion. Demographic information and indication for injection were recorded for each patient and office visit. Charts of patients with endophthalmitis were reviewed, and information was collected on presentation examination, culture data, and visual outcomes. RESULTS: During the study period, 101 932 bilateral same-day intravitreal anti-VEGF injections were performed over 50 966 office visits for 5890 patients. The mean (standard deviation) age of patients in this cohort was 74.2 (14.1) years and 60.6% of patients were female. The 2 most common indications for injection were neovascular age-related macular degeneration (54.3% of patients) and diabetic macular edema (35.4% of patients). Twenty-eight cases of endophthalmitis (0.027% of total injections) occurred during the study period. There were no cases of bilateral endophthalmitis, and no patients had more than 1 occurrence of endophthalmitis. CONCLUSIONS: In this large cohort of patients undergoing bilateral same-day intravitreal anti-VEGF injections, there were no cases of bilateral endophthalmitis. Additionally, the overall rate of unilateral endophthalmitis was low and comparable to prior studies of unilateral injections. These results support the safety of bilateral same-day intravitreal anti-VEGF treatment.
引用
- Borkar DS, Obeid A, Su DC, et al. Endophthalmitis Rates after Bilateral Same-Day Intravitreal Anti-Vascular Endothelial Growth Factor Injections. Am J Ophthalmol. 2018. PMID: 29981738. doi:10.1016/j.ajo.2018.06.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。